Although early initiation of glucagon-like peptide-1 receptor agonist (GLP-1ra) is recommended for patients with type 2 diabetes (T2D) who have established cardiovascular diseases (CVDs) or need to minimize hypoglycemia or promote weight loss [1], it is commonly observed that GLP-1ra is initiated in the later treatment course of T2D in real-world practice settings (especially after treatment failure under dual or triple glucose-lowering agents [GLAs] [2–6]). Here, GLP1R is linked to type 2 diabetes mellitus.